Sending Office: Honorable Eric Swalwell
Sent By:
andrew.ginsburg@mail.house.gov

http://e-dearcolleague.house.gov/DearColleague/Media/113/images/Members/Swalwell%2C%20Eric%20(CA15)/CongressLetterHeader.jpg

Find Treatments Now – Sign Bipartisan Letter to Speed Up and Improve Marijuana Research!

Signers:  Swalwell, Gaetz, Cohen, Panetta, Blumenauer, Gabbard, DeFazio, Gallego, Norton, Nadler, Schakowsky

April 17, 2019

Dear Colleague:

We urge you to join us in sending the letter below to the Department of Justice (DOJ) and Drug Enforcement Administration (DEA), asking them to speed up and improve the research process on cannabis.

Right now, the process to begin researching cannabis can take months to years, involving multiple government agencies.  The federal government also only allows one entity to grow cannabis for research purposes, and what it produces is of low quality and
not sufficient for all researchers.

Our letter asks DOJ and DEA to take steps to speed up research.  It also asks questions we previously included in a letter, to which we received no response, about the status of 26 applications by entities to grow cannabis for research purposes.

Please contact Andrew Ginsburg (andrew.ginsburg@mail.house.gov) with Rep. Swalwell, Devin Murphy (devin.murphy@mail.house.gov) with Rep. Gaetz,
or Matt Weisman (matthew.weisman@mail.house.gov) with Rep. Cohen if you have any questions or would like to sign on. 
The deadline is May 3, 2019.

Sincerely,

/s

/s

 

 

Eric Swalwell

Matt Gaetz

Member of Congress

Member of Congress

 

 

 

 

/s

 

 

 

Steve Cohen

 

Member of Congress

 

 

 

 

 

[date]

 

The Honorable William Barr                                                  The Honorable Uttam Dhillon

Attorney General                                                                    Acting Administrator

United States Department of Justice                                       Drug Enforcement Administration

950 Pennsylvania Avenue, NW                                              8701 Morrissette Drive

Washington, DC 20530                                                          Springfield, VA 22152

 

Dear Attorney General Barr and Acting Administrator Dhillon:

We write to urge you to do more to speed research on the medicinal benefits of cannabis.

Some of us have written to the Department of Justice (DOJ) and Drug Enforcement Administration (DEA) before on the topic of cannabis, and we write again because the matter is of such importance.  There is tremendous evidence that cannabis has the power to
treat a variety of medical ailments; that is why 33 states and the District of Columbia have made it legal for that purpose.

In fact, the federal government recognizes the healing properties of cannabis as well.  So far the Food and Drug Administration (FDA) has approved three compounds produced by the plant, known as cannabinoids, for medical use.  More research is needed, however,
to make additional products available.

Unfortunately, the federal government stands in the way.  The application process to research cannabis is one that is arduous and long.  First, one who wishes to engage in this research must at the very least work with three separate federal entities – the
National Institute on Drug Abuse (NIDA), DEA, and FDA.  Approval is required by DEA, which involves a site inspection, and FDA.  This is not including any involvement by governments at the state or local level. 

Second, there is only one federally-approved grower of cannabis for research in the United States – the University of Mississippi.  Researchers must wait to be provided the cannabis to begin their work.  Beyond any delays in time this adds, the cannabis
itself is generally regarded has having poor quality.  The University of Mississippi also does not offer cannabinoids.

It is thus not surprising that those who want to research cannabis are frustrated.  Some wait months or even years to have their applications approved.  And then they have to deal with raw materials that do not always lend themselves to proper research.

We recognize DEA has taken concrete steps to improve research prospects, but they do not go far enough.  Specifically, we applaud DEA for improving its application process for research by putting it entirely online in early 2018.  But, as John Hudak, a senior
fellow at the Brookings Institution, told Rolling Stone in February 2018, that is just a “very small drop in the bucket” in terms of speeding up the process.  And, we appreciate that DEA has increased its quota in 2019 for growing cannabis for research
purposes by more than five times, writing in the December 28, 2018 Federal Register notice approving the quota that it was due to “increased usage projections for federally approved research projects.”  But, that does not address any delays in receiving
cannabis, its quality, or what is presented as materials for research options.

We urge you then to go beyond these steps and do whatever you can to speed up and improve the research application process.  Please let us know what you are considering to change the application process so it moves more quickly and what additional resources
from Congress would help in that regard.

One action which would be beneficial is to act on one of the 26 pending applications to grow cannabis for research purposes; these applicants could provide better raw materials for research.  Some of us have written with questions about these applications
previously; we never received a response.  So, we would like to re-ask those questions here:

  1. What is the current status of the 26 cannabis manufacturer applications?  How long has each been pending before DOJ and DEA?
  1. What steps have the DEA and DOJ taken to review the cannabis manufacturer applications currently pending?  What are the reasons these applications have not been approved?
  1. When do you estimate the DEA and DOJ will complete their review of all of the cannabis manufacturing applications and begin approving some as new manufacturers?
  1. In the past 12 months, excluding Schedule I Bulk Manufacturer registrations for cannabis, how many other DEA registrations has DOJ reviewed?

We hope DOJ and DEA share our goal of bringing safe and effective medical treatments to those who are suffering as quickly as possible; we believe cannabis can be part of the solution, but we need more research to make that happen.

Thank you for reviewing our request, and we look forward to a prompt response.

Sincerely,

 

Cc:  Dr. Nora D. Volkow, Director, National Institute on Drug Abuse

Related Legislative Issues

Selected legislative information: Civil Rights, HealthCare, Judiciary

icon eDC logo e-Dear Colleague version 2.0
 
e-Dear Colleagues are intended for internal House use only.